title: ACUTE MACULAR NEURORETINOPATHY AFTER RANIBIZUMAB INJECTION IN A DIABETIC PATIENT.
abstract: OBJECTIVE
  To report a case of acute macular neuroretinopathy occurring after intravitreal ranibizumab injection for diabetic macular edema.
  
  
  METHODS
  Observational clinical case report.
  
  
  RESULTS
  The patient received an intravitreal ranibizumab (0.3 mg) injection for diabetic macular edema. Three days later, he had a decline in vision associated with a central and paracentral scotoma. Optical coherence tomography (OCT) demonstrated bandlike hyperreflectivity of the outer nuclear and plexiform layers corresponding to the patient's scotoma, consistent with the diagnosis of acute macular neuroretinopathy. There was spontaneous resolution of the abnormalities observed in optical coherence tomography, but only partial resolution of the scotoma was observed 4 months after presentation.
  
  
  CONCLUSIONS
  Diabetic retinopathy may be associated with acute macular neuroretinopathy. The temporal relationship between ranibizumab injection and the onset of acute macular neuroretinopathy in this case report raises the possibility of a causal relationship.
authors.affiliation: *Department of Ophthalmology, Rutgers-Robert Wood Johnson Medical School, Piscataway, New Jersey; †NJ Retina, New Brunswick, New Jersey; ‡Stein Eye Institute, UCLA, Los Angeles, California; and §Greater Los Angeles VA Healthcare Center, Los Angeles California.
authors.forename: H Matthew
authors.initials: HM
authors.lastname: Wheatley
authors.forename: David
authors.initials: D
authors.lastname: Sarraf
mesh_terms: D000208:Acute Disease; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000009:adverse effects*; D012164:Retinal Diseases / Q000139:chemically induced*; D012607:Scotoma / Q000139:chemically induced
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab